CEO: AstraZeneca Has ‘Winning’ Vaccine Formula

An illustration picture shows vials with COVID-19 Vaccine stickers attached and syringes, with the logo of the University of Oxford and its partner British pharmaceutical company AstraZeneca. (JUSTIN TALLIS/AFP via Getty Images)

The coronavirus vaccine developed by the British drugs group AstraZeneca and the University of Oxford has achieved a “winning formula” for efficacy, the company’s chief executive said in an interview.

The vaccine, currently being evaluated by Britain’s independent medicines regulator, provides “100 percent protection” against severe COVID-19 disease requiring hospitalization, Pascal Soriot said in an interview with the Sunday Times newspaper.

He added that he believes trials will show his firm has achieved a vaccine efficacy equal to Pfizer-BioNTech at 95% and Moderna at 94.5%.

“We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else,” Soriot said.

To Read The Full Story

Are you already a subscriber?
Click to log in!